Intra-arterial chemotherapy of primary brain tumors

Newton, Herbert B.

doi:10.1007/s11864-005-0030-1

Cited by 43 publications

(31 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, its high toxicity led to a reduction of the mean survival time of the animals. This result is in agreement with previous report suggesting that treatment with cisplatin is not appropriated in the management of brain tumor [23].…”

Section: Discussionsupporting

confidence: 94%

“…This low uptake of drugs did not result in a significant anti-tumor effect, as measured by the mean survival time of the rats. When IV administrations were combined to radiotherapy, only treatment with Lipoxal ™ (the liposomal formulation of oxaliplatin) improved slightly the therapeutic efficacy (P = 0.045) Our results with Fischer rats are in line with clinical trials on GBM patients treated with IV platinum where a modest therapeutic efficiency was reported [23]. It is noteworthy that cisplatin was the only drug to accumulate significantly in the brain tumor after IV procedure.…”

Section: Discussionsupporting

confidence: 83%

See 1 more Smart Citation

Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain

et al. 2013

View full text Add to dashboard Cite

Treatment of glioblastoma with platinum compounds modestly improves progression-free survival and may cause toxic effects which prevent use at higher dose that would otherwise improve the antineoplastic effect. To reduce toxicity, we propose to encapsulate the platinum drug in a liposome. We have also tested three methods of drug administration (intra-venous, intra-arterial and intra-arterial combined with blood brain barrier disruption) to determine which one optimizes the tumor cell uptake, limits the toxicity and delivers the best concomitance effect with radiotherapy. Cisplatin, oxaliplatin, their respective liposomal formulations, Lipoplatin ™ and Lipoxal ™ , and carboplatin were assessed in F98 glioma, orthotopically implanted in Fischer rats. We found that the modest accumulation of drugs in tumor cells after intra-venous injection was significantly improved when the intra-arterial route was used and further increased after the transient opening of the blood brain barrier with mannitol. The liposomal formulations have largely reduced the toxicity and have allowed a better exploitation of the anti-cancer activity of platinum agent. Although the liposomes Lipoplatin ™ and Lipoxal ™ have shown a similar ability to CIHR Author ManuscriptCIHR Author Manuscript CIHR Author Manuscript that of carboplatin, to accumulate in brain tumors, the highest additive effect with radiotherapy was obtained with carboplatin. We conclude that the intra-arterial infusion of carboplatin or Lipoxal ™ in concomitance with radiation therapy leads to the best tumor control as measured by an increase of mean survival time in Fischer rats implanted with the F98 glioma with a benefit in survival time of 13.4 and 6.5 days respectively compared to intra-venous.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Discussionsupporting

confidence: 83%

Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Figure Numerous studies have reported on the use of IA therapy. A variety of single agents have been utilized including nitrosoureas, platinum analogs, 5-FU, etoposide, or in combination with systemic chemotherapy 3 . IA administration techniques have also been used to deliver adenoviral 4 or HSV 5 vectors to human brain tumors in mice and rats with some evidence of inhibition of tumor growth.…”

Section: Resultsmentioning

confidence: 99%

Vascular Distribution of Glioblastoma Multiforme at Diagnosis

Yohay¹,

Wolf²,

Aronson

et al. 2013

Interv Neuroradiol

View full text Add to dashboard Cite

Treatment of high-grade gliomas with selective intra-arterial (IA) administration of chemotherapies has been proposed, and utilized as a therapeutic modality. This approach offers the conceptual benefit of providing maximal delivery of the agent to the tumor bed, while potentially reducing systemic exposure to the agent. This retrospective study was designed to determine the vascular distribution of glioblastoma multiforme (GBM) at the time of diagnosis in an effort to determine what proportion of patients would likely be candidates for this approach. The preoperative MRI scans of 50 patients with GBM were analyzed and compared to published normative data of intracranial vascular distribution. Vascular distribution was determined by analyzing post-gadolinium axial and coronal T1 images, axial T2 images, and axial T2 images with an additional 1 cm margin (T2 + 1 cm) added in all dimensions. T1 analysis demonstrated 60% of tumors in a single vascular distribution. T2 analysis of these tumors reduced that number to 34%. When the T2 + 1 cm margin was utilized, only 6% of tumors were in a single vascular distribution. 66% of tumors were limited to the anterior circulation on T1 imaging but only 34% on T2 + 1 cm imaging. 30% of tumors were also within the distribution of the anterior choroidal artery. These findings suggest that the use of selective IA administration of agents is necessarily limited to a fraction of presenting patients or will require administration via multiple cerebral arteries.

show abstract

“…79 To date, superselective intraarterial cerebral infusion has been successfully leveraged for the treatment of high-grade gliomas and retinoblastomas. 3,67,86 In large-vessel stroke, intraarterial delivery of neuroprotectants can occur prior to, or following, clot extraction. If an agent is delivered distal to a thrombus prior to recanalization, it will likely remain in the tissue bed until flow is restored.…”

Section: Intraarterial Neuroprotectant Deliverymentioning

confidence: 99%

Neuroprotective delivery platforms as an adjunct to mechanical thrombectomy

Babadjouni¹,

Walcott

Liu³

et al. 2017

FOC

View full text Add to dashboard Cite

Despite the success of numerous neuroprotective strategies in animal and preclinical stroke models, none have effectively translated to clinical medicine. A multitude of influences are likely responsible. Two such factors are inefficient recanalization strategies for large vessel occlusions and suboptimal delivery methods/platforms for neuroprotective agents. The recent endovascular stroke trials have established a new paradigm for large vessel stroke treatment. The associated advent of advanced mechanical revascularization devices and new stroke technologies help address each of these existing gaps. A strategy combining effective endovascular revascularization with administration of neuroprotective therapies is now practical and could have additive, if not synergistic, effects. This review outlines past and current neuroprotective strategies assessed in acute stroke trials. The discussion focuses on delivery platforms and their potential applicability to endovascular stoke treatment.

show abstract

Intra-arterial chemotherapy of primary brain tumors

Cited by 43 publications

References 61 publications

Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain

Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain

Vascular Distribution of Glioblastoma Multiforme at Diagnosis

Neuroprotective delivery platforms as an adjunct to mechanical thrombectomy

Contact Info

Product

Resources

About